Business
Starpharma hunts for cash as it speeds up COVID nasal spray treatment – Sydney Morning Herald
The Melbourne biotech is in a trading halt as it launches a placement for a COVID treatment it hopes to be ready by next year.
Starpharma shares have been on a tear over the past month since the business started to update the market on progress about the nasal spray. Shares have jumped from $1.41 to $1.60 over the past month.
The nasal spray repurposes Starpharma’s antiviral product SPL7013, which is already used in its sexual health products including condoms. The company hopes the compound will bind to the SARS-COV-2 spike protein and block the virus from attaching to cells.
Earlier this month the company released d…
-
General22 hours agoAlgal bloom ‘disaster’ prompts royal commission call as impact spreads to mussel farms
-
Noosa News22 hours agoE-bikes shouldn’t be banned. The illegal ones are already illegal
-
General19 hours agoChina was the big disruptor in our region. Now the US is determined to take that title
-
General18 hours agoSpaceX to invest $3 billion in Musk’s xAI startup